Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ict-107
- Development stage
- Discontinued
- Lead developer
- EOM Pharmaceutical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
ICT-107 is an autologous dendritic cell-based cancer vaccine developed for the treatment of newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The therapy consists of a patient's own dendritic cells, which are pulsed with six synthetic peptides corresponding to tumor-associated antigens commonly found on glioblastoma cells—specifically AIM-2, MAGE-1, TRP-2, gp100, HER2 (epidermal growth factor receptor 2), and IL13Rα2. When these antigen-loaded dendritic cells are reintroduced into the patient, they stimulate cytotoxic T-cell responses targeting GBM tumor cells expressing these antigens. ICT-107 was granted orphan drug status by both the FDA and EMA for glioblastoma but has not achieved regulatory approval due to lack of statistically significant overall survival benefit in clinical trials[1][3][4][8].
- Other names
- ICT 107ICT107ICT-107
02
Targets
AIM2 inflammasome (Absent in melanoma 2 inflammasome)DCT (L-dopachrome tautomerase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)IL13RA2 (Interleukin-13 receptor subunit alpha 2)MAGEA1 (Melanoma-associated antigen 1)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on ict-107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ict-107.